Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Wilms Tumor 9Glioma 9Osteosarcoma 8Neuroblastoma 8Multiple Myeloma 8Leukemia, Myeloid, Acute 8Sarcoma 7Rhabdoid Tumor 7Prostatic Neoplasms 7Neoplasm Metastasis 7Lymphoma, Non-Hodgkin 7Hepatoblastoma 7Rhabdomyosarcoma 6Neuroectodermal Tumors, Primitive, Peripheral 6Medulloblastoma 6Lymphoma 6Lung Neoplasms 6Histiocytosis, Langerhans-Cell 6Ependymoma 6Colorectal Neoplasms 6Breast Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myelodysplastic Syndromes 5Central Nervous System Neoplasms 5Carcinoma, Hepatocellular 5Sarcoma, Ewing 4Ovarian Neoplasms 4Melanoma 4Carcinoma, Non-Small-Cell Lung 4Rectal Neoplasms 3

Interventions

Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2tazemetostat 1pembrolizumab 1atezolizumab 1X-Rays 1Tiragolumab 1Phantoms, Imaging 1Fluorodeoxyglucose F18 1Cetuximab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chordoma × X-Rays × 90 days × Clear all
NCT05286801 2026-05-13

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
86 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡